Physiologie, Pathologie und pharmakologische Effekte des Prostazyklins

Zusammenfassung

PGI₂ bewirkt über die Erhöhung intrazellulärer cAMP-Spiegel eine Hemmung der Thrombozytenaggregation. Seine zweite Hauptwirkung ist eine Vasodilatation. Die Synthese von PGI₂ wird durch eine schädigende Noxe an der Gefäßwand aktiviert, in welcher PGI₂ hauptsächlich im Endothel, aber auch in den glatten Muskelzellen synthetisiert wird. Es besteht eine enge Interaktion zwischen korpuskulären Blutbestandteilen, aber auch verschiedenen Plasmafaktoren und der Gefäßwand, die insbesondere bei Verletzungen im Hinblick auf die lokale Hämostase mit Thrombozytenaggregation, Blutgerinnung und lokaler fibrinolytischer Aktivität von Bedeutung zu sein scheint. Mit Ausnahme einiger weniger spezieller Indikationen scheint das natürliche, instabile PGI₂ aber bislang nur von limitiertem therapeutischem Nutzen zu sein.

• LITERATUR

• 1 Aanderud S, Krane H, Nordoy A. Influence of glucose, insulin and sera from diabetic patients on the prostacyclin synthesis in vitro in cultured human endothelial cells. Diabetologica 1985; 28: 641-4.
• 2 Acharya S B, MacIntyre D E. Platelet products and vascular PGI₂ production. Prostaglandins Leukotrienes Med 1983; 10: 73-81.
• 3 Akai T, Naka K, Okuda K, Takemura T, Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metabol Res 1983; 15: 523-6.
• 4 Bergström S, Carlson L A, Weeks J R. The prostaglandins: a family of biologically active lipids. Pharmacol Rev 1968; 20: 1-48.
• 5 Boeynaems J M, Galand N. Stimulation of vascular prostacyclin synthesis by extracellular ADP and ATP. Biochem Biophys Res Commun 1983; 112: 290-6.
• 6 Boeynaems J M, Galand N, Ketelbant P. Prostacyclin production by the deendothelialized rabbit aorta. J Clin Invest 1985; 76: 7-14.
• 7 Bunting S, Moncada S, Vane J R. The prostacyclin-thromboxane A₂ balance: pathophysiological and therapeutic implications. Br Med Bull 1983; 39: 271-6.
• 8 Bydlowski S P, Yunker R L, Campaigne B N, Kotogal U R, Subbiah M T R. Human breast milk contains a factor which markedly stimulates aortic prostacyclin synthesis. Biochim Biophys Acta 1986; 878: 1-6.
• 9 Chesterman C N, Owe-Young R, Macpherson J, Krillis S A. Substrate for endothelial prostacyclin production in the presence of platelets exposed to collagen is derived from platelets rather than the endothelium. Blood 1986; 67: 1744-50.
• 10 Coughlin S R, Moskowitz M A, Zetter B R, Antoniades H N, Levine L. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature 1980; 288: 600-2.
• 11 Cramer E B, Pologe L, Pawlowski N A, Cohn Z A, Scott W A. Leukotriene C promotes prostacyclin synthesis by human endothelial cells. Proc Natl Acad Sci USA 1983; 80: 4109-13.
• 12 D’Angelo V, Villa S, Mysliwiec M, Donati M B, de Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemostas 1978; 39: 535-6.
• 13 Dembinska-Kiec A, Zmuda A, Grodzinska L, Bieron K, Basista M, Kedzior A, Kostka-Trabka E, Telesz E, Zelasny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 1981; 827-32.
• 14 Dembinska-Kiec A, Kostka-Trabka E, Gryglewski R J. Effect of prostacyclin on fibrinolytic activity in patients with atherosclerosis obliteranç. Thromb Haemostas 1982; 47: 190.
• 15 Ditter H, Heinrich D, Matthias F R, Sellmann-Richter R, Wagner W L, Hehrlein F W. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of betathromboglobulin, platelet factor 4, thromboxane B₂, 6-keto-prostaglandin F_la and heparin. Thromb Res 1983; 32: 393-408.
• 16 Dutta-Roy A K, Ray T K, Sinha A K. Prostacyclin stimulation of the activation of blood coagulation factor X by platelets. Science 1986; 231: 385-8.
• 17 Etingin O R, Weksler B B, Hajjar D P. Cholesterol metabolism is altered by hydrolytic metabolites of prostacyclin in arterial smooth muscle cells. I Lipid Res 1986; 27: 530-6.
• 18 Fitscha P, Kaliman I, Sinzinger H. Platelet sensitivity to antiaggregatory prostaglandins (PGEj, D₂, I₂) in patients with peripheral vascular disease. Am I Haematol 1985; 19: 13-9.
• 19 FitzGerald G A, Oates I A. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35: 633-40.
• 20 FitzGerald G A, Smith B, Pedersen A K, Brash A R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-8.
• 21 Gryglewski R J. Deaggregatory action of prostacyclin in vivo and its enhancement by theophylline. Prostaglandins 1978; 15: 637-44.
• 22 Guivernau M, Baraona E, Lieber C S. Acute and chronic effects of ethanol and its metabolites on vascular production of prostacyclin in rats. J Pharmacol Exp Ther 1987; 240: 59-64.
• 23 Hall E R, Papp A C, Seifert W E, Wu K K. Stimulation of endothelial cell prostacyclin formation by interleukin-2. Lymphokine Res 1986; 05: 87-96.
• 24 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-8.
• 25 Hope W, Martin T J, Chesterman C N, Morgan F J. Human thromboglobulin inhibits PGI₂ production and binds to a specific site in bovine aortic endothelial cells. Nature 1979; 282: 210-3.
• 26 Jaschonek K, Karsch K R, Weisenberger H, Tidow S, Faul C, Renn W. Platelet prostacyclin binding in coronary artery disease. J Am Coll Cardiol 1986; 08: 259-66.
• 27 Johnson E J, Mackie I J, Machin S J, Brozovic B. Preservation of platelet function in cryopreserved platelet concentrated with prostacyclin. Clin Lab Haematol 1984; 06: 141-4.
• 28 Johnson M, Harrison H E, Raftery A T, Elder J B. Prostacyclin and diabetes. In: Clinical Pharmacology of Prostacyclin. Lewis P J, O’Grady J. (eds). New York: Raven Press; 1981: 105-12.
• 29 Johnson R A, Morton D R, Kinner J H, Gorman R R, McGuire J C, Sun F F, Wittacker N, Bunting S, Salmon J, Moncada S, Vane J R. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976; 12: 915-28.
• 30 Jolan H, Muszbek L, Stadler I, Fesus L. Inhibition of platelet factor 3 availability by prostacyclin. Prostaglandins 1980; 20: 935-45.
• 31 Kiernan F J, Kluger J, Regnier J C, Rutkowski M, Fieldman A. Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J 1986; 56: 428-32.
• 32 Kuehl F A, Dougherty H W, Ham E A. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33: 1-5.
• 33 Lewis P J, Dollery C T. Clinical pharmacology and potential of prostacyclin. Br Med Bull 1983; 39: 281-4.
• 34 Marcus A J, Weksler B B, Jaffe E A, Broekman E J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-86.
• 35 Menitove J E, Frenzke M, Aster R H. Use of prostacyclin to inhibit activation of platelets during preparation of platelet concentrates. Transfusion 1984; 24: 528-31.
• 36 Miller D K, Sadowski S, Soderman D D, Kuehl F A. Endothelial cell prostacyclin production induced by activated neutrophils. J Biol Chem 1985; 260: 1006-14.
• 37 Moncada S. Prostacyclin/thromboxane-mediated mechanisms in platelet-vascular wall interactions. Adv Prostaglandin Thromboxane Leukotriene Res 1985; 15: 507-12.
• 38 Moncada S, Vane J R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A₂, and prostacyclin. Pharmacol Rev 1979; 30: 293-333.
• 39 Moncada S, Gryglewski R, Bunting S, Vane J R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
• 40 Musial J, Wilczynska M, Sladek K, Cierniewski C S, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31: 61-70.
• 41 Neri G GSerneri, Modesti P A, Fortini A, Abbate R, Lombardi A, Gensini G F. Reduction of prostacyclin platelet receptors in active spontaneous angina. Lancet 1984; II: 838-41.
• 42 Nizankowski R, Krolikowski W, Bielatowicz J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study. Thromb Res 1985; 37: 21-8.
• 43 Oates J A, FitzGerald G A. Endogenous biosynthesis of prostacyclin and thromboxane A₂ and the prevention of vascular occlusion in man. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 115-23.
• 44 Orchard M A, Blair I A, Dollery C T, Lewis P J. Blood can synthesize prostacyclin. Lancet 1983; II: 565.
• 45 Payton C D, Belch J J F, Boulton J MJones. Successful treatment of thrombotic thrombocytopenic purpura by epoprostenol infusion. Lancet 1985; I: 927-8.
• 46 Pedersen A K, Watson M L, FitzGerald G A. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF_1α . Thromb Res 1983; 33: 99-103.
• 47 Prentice C R M, Belch J J F. Prostacyclin in Raynaud’s syndrome. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 7-13.
• 48 Prentice C R M, Belch J J F, McKay A, McArdle B, Leiberman P, Pollock J G, Lowe G D O, Forbes C D. Prostacyclin in severe arterial disease. In: Prostacyclin Clinical Trials. Gryglewski R J, Szczeklik A, McGiff J C. (eds). New York: Raven Press; 1985: 1-5.
• 49 Price R M, Gersten D M, Ramwell P W. Macromolecules mediate prostacyclin release from human umbilical artery. Biochim Biophys Acta 1985; 836: 246-54.
• 50 Reinders J H, Brinkman H J M, von Mourik J A, de Groot P G. Cigarette smoke impairs endothelial cell prostacyclin production. Arteriosclerosis 1986; 06: 15-23.
• 51 Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174-6.
• 52 Rylance P B, Gordge M P, Ireland H, Lane D A, Weston M J. Hemodialysis with prostacyclin (epoprostenol) alone. ProcEur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 281-6.
• 53 Schafer A I, Crawford D D, Gimbrone M A. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 1984; 73: 1105-12.
• 54 Schrör K. Prostaglandins, other eicosanoids and endothelial cells. Basic Res Cardiol 1985; 80: 502-14.
• 55 Silberbauer K, Scherntaner G, Sinzinger H, Piza-Katzer H, Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. N Eng J Med 1979; 300: 366-7.
• 56 Sinha A K, Dutta-Roy A K, Chin H C, Stewart G J, Colman R W. Coagulant factor Xa inhibits prostacyclin formation in human endothelial cells. Role of factor V. Arteriosclerosis 1985; 05: 244-9.
• 57 Sinzinger H, Feigl W, Silberbauer K. Prostacyclin generation in atherosclerotic arteries. Lancet 1979; II: 469.
• 58 Sinzinger H, Silberbauer K, Horsch A K, Gall A. Decreased sensitivity of human platelets to PGI₂ during long-term intraarterial prostacyclin infusion in patients with vascular disease a rebound phenomenon?. Prostaglandins 1981; 21: 49-51.
• 59 Sinzinger H, O’Grady J, Cromwell M, Hofer R. Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic graft. Lancet 1983; I: 1275-6.
• 60 Sinzinger H, Leithner C, Silberbauer K. Rebound platelet activations during continuous epoprostenol infusion. Lancet 1984; II: 759.
• 61 Sinzinger H, O’Grady J, Fitscha P, Kaliman J. Effect of epoprostenol on platelet deposition on synthetic artery grafts. Lancet 1984; II: 1212.
• 62 Sinzinger H, Matejka M, Steurer G, Kaliman J, Ettl K. The interaction between the platelet derived growth factor (PDGF) and prostaglandin (PG) I₂ is important for atherogenesis. 6th International Conference on Prostaglandins and Related Compounds. Abstract Book; 1986: 14.
• 63 Smith W. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Ann Rev Physiol 1986; 48: 251-62.
• 64 Szczeklik A, Kopec M, Sladek K, Musial J, Chmielewska J, Teisseyre E, Dudek-Wojciechowska G, Palester-Chlebowczyk M. Prostacyclin and the fibrinolytic system in ischemic vascular disease. Thromb Res 1983; 29: 655-60.
• 65 Vane J R. Clinical potential of prostacyclin. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 11: 449-56.
• 66 Von Euler U S. Über die spezifische blutdrucksenkende Substanz des menschlichen Prostataund Samenblasensekretes. Klin Wochenschr 1935; 33: 1182-3.
• 67 Wautier J L, Pintigny D, Maclouf J, Wautier M P, Corvazier E, Caen J. Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium. J Lab Clin Med 1986; 107: 210-5.
• 68 Weksler B B. Prostaglandins and vascular function. Circulation 1984; 70 (Suppl III): 63-71.
• 69 Weksler B B, Ley C W, Jaffe E A. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and the ionophore A 23187. J Clin Invest 1978; 62: 923-30.
• 70 Weston M J. Prostacyclin and extracorporeal circulation. Br Med Bull 1983; 39: 285-8.
• 71 Zwaal R F, Comfurius P, Hemker H C, Bevers E M. The inhibition of platelet prothrombinase activity by prostacyclin. Haemostasis 1984; 14: 320-4.